Inmagene to secure licence for two HUTCHMED drug candidates

05 Feb 2024
www.pharmaceutical-technology.com
Phase 1License out/inOrphan DrugPhase 2
Inmagene to secure licence for two HUTCHMED drug candidates
Preview
Source: Pharmaceutical Technology
The licensing is part of a collaboration initiated by the companies in 2021 for developing drug candidates in the I&I field. Credit: murat photographer / Shutterstock.com.
Inmagene Biopharmaceuticals has exercised its option to secure an exclusive global and royalty-bearing licence for two Hutchmed drug candidates, IMG-007 and IMG-004, to treat immune and inflammatory (I&I) ailments.
The strategic move also grants Inmagene the right to sublicense the assets and is part of a collaboration initiated in 2021 to develop and commercialise a portfolio of drug candidates in the I&I field.
HUTCHMED will receive $92.5m in development milestone payments and $135m in commercial milestone payments for each candidate. The payments are apart from the sales-based royalties for the drugs.
IMG-007 is a non-depleting humanised anti-OX40 monoclonal antibody (mAb), while IMG-004 is an oral non-covalent and reversible Bruton’s tyrosine kinase inhibitorBruton’s tyrosine kinase inhibitor.
IMG-007 is undergoing Phase IIa clinical trials for moderate-to-severe atopic dermatitis and alopecia areata.
See Also:Contentious Medicare price negotiations underway as US drug prices rise
Inmagene to secure licence for two HUTCHMED drug candidates
Preview
Source: Pharmaceutical Technology
AnaMar secures double orphan drug designation for systemic sclerosis drug
Inmagene to secure licence for two HUTCHMED drug candidates
Preview
Source: Pharmaceutical Technology
The mAb has an extended half-life and silenced antibody-dependent cell-mediated cytotoxicity function, and plays a crucial role in T cell activation and survival.
Nonclinical studies have shown that IMG-007 can hinder the OX40-OX40L signalling pathway.
According to a Phase I single ascending dose (SAD) study data, the drug showed a 31-day half-life at therapeutic dose levels, which could allow for dosing every 12 weeks and a safety profile that stands out from similar molecules in development.
IMG-004 is a highly selective and brain-permeable oral agent tailored to treat inflammatory and autoimmune diseases long-term.
Phase I SAD study results indicate that the candidate has an extended half-life and a lasting pharmacodynamic effect, which could enable once-daily dosing.
Following the ongoing Phase I multiple ascending dose study, IMG-004 will be assessed in treating chronic spontaneous urticaria and rheumatoid arthritis.
In addition to these licensed assets, Inmagene’s in-house IMG-008, a long-acting anti-IL-36R mAb, is set to enter a global Phase I trial, further expanding its portfolio in the I&I therapeutic area.
Inmagene CEO Jonathan Wang stated: “Our strategic partnership with HUTCHMED has allowed us to take IMG-007 and IMG-004, two assets with best-in-class potential, from pre-clinical to clinical development.
“Obtaining the worldwide exclusive rights is another step forward in our journey to become a global leader in novel drug development for I&I diseases.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.